Mesenchymal stem cells (MSC) attenuate albuminuria and preserve normal renal histology in diabetic mice. However, the effects of MSC on glomerular podocyte injury remain uncertain. The aim of this study was to evaluate the effects of MSC on podocyte injury in streptozotocin (STZ)-induced diabetic rats. Thirty days after diabetes induction by STZ injection (65 mg/kg, intraperitoneally) in Sprague-Dawley rats, the diabetic rats received medium or 2 Â 10 6 enhanced green fluorescent protein-labeled MSC via the renal artery. In vivo tracking of MSC were followed by immunofluorescence analysis. Diabetes-related physical and biochemical parameters were measured on day 60 after the MSC infusion. The expression of podocyte markers (nephrin and podocin), podocyte survival factors (VEGF and BMP-7), and the ultrastructural pathology of podocytes were also assessed. MSC were only detected in the glomeruli from the left kidney receiving MSC infusion. Compared with medium-treated diabetic rats, rats treated with MSC showed a suppressed increase in kidney weight, kidney to body weight index, creatinine clearance rate and urinary albumin to creatinine ratio; however, the treatment had no effect on blood glucose or body weight levels. Furthermore, the MSC treatment reduced the loss of podocytes, effacement of foot processes, widening of foot processes, thickening of glomerular basal membrane Q 1 and loss of glomerular nephrin and podocin. Most importantly, MSC-injected kidneys expressed higher levels of BMP-7 but not of VEGF. Our results clearly demonstrated that intra-
INTRODUCTION
Diabetic nephropathy (DN) is a major complication of diabetes and represents the leading cause of end-stage renal disease worldwide [1] . To date, there is no cure for DN. Drugs that decrease blood glucose, lower blood pressure, or inhibit the actions of the hormone angiotensin can delay, but not eliminate, the onset of DN. Thus, the development of novel therapeutic strategies that could specifically target DN is necessary.
Podocytes are highly specialized cells with important roles in maintaining the glomerular filtration barrier and producing growth factors for both the mesangial and endothelial cells [2] . Recent studies have shown that progressive podocyte injury, called podocytopathy, is one of the key events in the pathogenesis of DN [3] . Podocyte loss and injury are associated with the development of albuminuria and the acceleration of glomerular structural abnormalities [2, 4, 5] . Thus, there is a need to clarify the underlying pathogenesis of podocyte injury and the associated alterations in the function of the glomerular filtration barrier to develop a novel therapeutic strategy for the prevention and amelioration of podocyte injury.
Stem cell therapy is a novel strategy for various diseases and has the potential to be more effective than single-agent drug therapies [6] . Several studies have shown that mesenchymal stem cell (MSC) therapy improves microalbuminuria and preserves the normal renal histology of diabetic mice [7, 8] . However, the exact mechanisms underlying their therapeutic effects on microalbuminuria have not been clearly defined. It remains unknown whether the contribution of MSC to reducing microalbuminuria is associated with the improvement of podocyte injury. Based on these findings, we hypothesized that the transplantation of MSC may be a potential therapeutic approach for diabetic podocyte injury.
In the present study, we aim to evaluate whether MSC could exert their protective effects against diabetic podocyte injury. Here, our study provides the first evidence that MSC therapy may constitute a new therapeutic intervention to target podocyte damage.
MATERIALS AND METHODS

Experimental Animal
Adult male Sprague-Dawley (SD) rats (weight, 180 g to 200 g) from the laboratory animal center of Xinqiao hospital were maintained under specific pathogen-free conditions at the animal care facilities. After one week of adaptation, diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ) (65 mg/kg; Sigma, St Louis, MO) in the rats following overnight fasting. Rats with a blood glucose level over 16.7 mmol/L were considered diabetes-induced rats and were used in the study. Diabetic rats received daily injections of long-acting insulin in doses adjusted individually (ranging from 1 U to 4 U) to maintain blood glucose levels between 16 mmol/L and 28 mmol/L and to avoid ketonuria. All animal procedures were carried out according to the guidelines of the Animal Ethics Committee of the Third Military Medical University, which are consistent with the NIH Guide for the Care and Use of Laboratory Animals.
Isolation, Culture and Characterization of MSC
MSC were obtained from the femurs and tibias of adult male SD rats and cultured in DMEM/F12 medium (Gibco, Gaithersburg, MD) containing 10% fetal bovine serum (Gibco), 100 U/mL penicillin, and 100 mg/mL streptomycin. The phenotypic properties of MSC were performed by flow cytometry analysis using the following markers: CD29, CD44, CD34, and CD45 [9, 10] . MSC were expanded in osteogenic or adipogenic differentiation media (Cyagen Biosciences, Guangzhou, China) in six-well plates after the third passage. Osteogenic and adipogenic differentiations were tested using standard protocol from Cyagen Biosciences Inc.
Cell Labeling for In Vivo Tracking
To assess the intrarenal localization of MSC, we used enhanced green fluorescent protein (EGFP) (Cyagen Biosciences) as a cell tracker in the tracking experiments. Cells were labeled using transduction with lentiviraltransduced EGFP, according to the manufacturer's protocol. Briefly, MSC after the third passage were seeded at 2 Â 10 6 cells in six-well plates 24
hours before transduction. The next day, 1 mL MSC medium per well containing 8 mg/mL polybrene (Sigma) and viral were added to the cells at 20 multiplicities of infection. After viral addition, cells were incubated at 37 C in 5% CO 2 for 6 hours. The medium was replaced by a fresh complete culture solution, and cells were cultured until further experimentation. Selection was completed 72 hours after incubation with 10 mg/mL puromycin.
MSC Administration and Experimental Design
Thirty days after the injection of STZ, DN rats were randomly divided into 2 groups: DN rats treated with medium (DNþmedium, n ¼ 10) and DN rats treated with MSC (DNþMSC, n ¼ 14). Nondiabetic rats were used as the normal control group (NC, n ¼ 6). MSC-treated DN rats were injected with 2 Â 10 6 MSC (suspended in 1 mL serum-free medium) via the left renal artery, as described previously [11] , and DNþmedium rats received an equal volume of medium. In this procedure, 2 rats that died of anesthesia or during surgery were excluded; one died in each group. Then, the rats were housed under specific pathogen-free conditions with a standard diet and water for 60 days before they were sacrificed (Figure 1 ). At the end of the experiment, the surviving rats were sacrificed, and the left and right kidneys of MSCtreated rats (n ¼ 9) and medium-treated rats (n ¼ 8) were harvested, weighed, and processed for histological and biochemical evaluation.
EGFP-MSC Detection
At 24 hours and on day 60 after MSC injection, 2 MSC-treated rats were sacrificed, and their kidney tissues were embedded in Tissue-Tek O.C.T. compound (Sakura Finetek, Torrance, CA) and frozen. The tissues were sectioned into 8-mm samples using a cryostat microtome at À22 C. After fixation in acetone for 5 minutes, the sections were then covered with fluorescent antifade mounting medium. The 488-nm line of the laser was used for EGFP fluorescence excitation, and renal tissue background autofluorescence was detected at 555 nm. We used laser scanning confocal microscopy (Leica Microsystems, Wetzlar, Germany) for the 2 fluorescent analyses.
Physical and Biochemical Analysis
The body weight, kidney weight, and blood glucose were measured at the conclusion of the experiment. The serum creatinine levels were measured in the blood obtained from the retro-orbital sinus at the time of the sacrifice using an automatic biochemistry analyzer (Hitachi, Tokyo, Japan). The creatinine clearance rate was calculated as urinary creatinine Â urine volume / serum creatinine and expressed as milliliters per minute. Urinary albumin excretion was expressed as the urinary albumin to creatinine ratio. Urinary albumin levels were measured in morning spot urine samples by a protein assay kit (Bio-Rad, Hercules, CA). After diabetes induction, albumin to creatinine ratios were determined every 30 days.
Renal Morphology
The paraffin sections were stained with Periodic Acid Schiff (PAS). The extent of glomerular damage was expressed as the percentage of glomeruli presenting mesangial expansion [12] or glomerulosclerosis, as described previously [13] . For ultrastructural evaluation, 1 mm 3 pieces of renal cortex were fixed in 2.5% glutaraldehyde in .1 M phosphate buffer (pH, 7.4) for transmission electron microscopy. Electron micrographs of 5 blocks per kidney (10 photographs per block) were obtained at a final magnification of 8900-or 12,500-fold for each rat using a systematic uniform random sampling protocol. To ensure randomized sampling and avoid repetitious counting for podocytes in cross-sectional profiles, .5-mm sections taken at least 200 mm (average glomerular diameter) apart were cut and collected. The average number of podocytes was measured by manually tracing along the glomerular basal membrane Q 2
(GBM) on a video screen. Podocytes were defined as those cells residing within the glomerular tuft but outside the GBM. The podocyte quantity, expressed as the number of podocytes per 2.5 mm GBM, was calculated by computerized measurement using the Image Measurement System (Leica Qwin Lite, Wetzlar, Germany) [14] . At the higher magnification, GBM thickness was defined as the distance perpendicular to the GBM between the endothelial and podocyte plasma membranes, measured with the aid of Image-Pro Plus (Media Cybernetics, Silver Spring, MD). The analysis of podocyte foot process effacement was expressed as the arithmetic mean of the podocyte foot processes width (FPW), which was calculated by dividing the total length of the GBM length by the total number of foot processes according to published methods [15] .
A correction factor of p/4 was used to correct for presumed random variation in the angle of the section relative to the long axis of the podocyte. All measurements were performed by the same technician who was unaware of their origin [16] . The podocyte and GBM data were shown as box-and-whisker plots using the SigmaPlot 12.0 software (Systat, San Jose, CA).
Immunofluorescence
Immunofluorescent staining was performed with the specific podocyte markers nephrin and podocin for localization. Frozen sections (5 mm) were fixed in cold acetone for 10 minutes at À20 C and incubated with wash buffer containing .1% Triton X-100 at room temperature for 20 minutes to prevent nonspecific binding. Subsequently, the sections were incubated overnight at 4 C with polyclonal rabbit anti-nephrin (1:200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA) and polyclonal rabbit anti-podocin (1:100 dilution; Santa Cruz Biotechnology) antibodies diluted in bovine serum albumin at 1%. After being rinsed in phosphate buffered saline Q 3
, the TRITC-labeled goat antirabbit secondary antibody was incubated away from light at 37 C for 30 minutes. Negative controls were run by replacing the primary antibody with phosphate buffered Q 4 saline. Staining was evaluated under laser scanning confocal microscopy (Leica).
Western Blot Analysis
The renal cortex was homogenized in lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) on ice for 30 minutes. The proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and electrotransferred to polyvinylidene difluoride nitrocellulose membranes (Roche). After blocking in 5% nonfat dried milk for 1 hour at room temperature, the membranes were incubated with polyclonal rabbit antinephrin (1:700 dilution; Santa Cruz) and polyclonal antipodocin (1:500 dilution; Santa Cruz) antibodies overnight at 4 C. After washing, the membrane was incubated for 1 hour at room temperature with goat antirabbit IgG horseradish peroxidase-linked antibody (1:2000 dilution; Zhongshan Goldenbridge Biotechnology, Beijing, China). The membrane-bound antibody detected was incubated with a chemiluminescent reagent plus (Thermo Fisher Scientific Inc, Rockford, IL) and captured on Gel Documentation systems (Alpha Innotech, Santa Clara, CA). Band intensities were quantified Figure 1 . Mesenchymal stem cells (MSC) administration and experimental design. To induce diabetes, the rats were injected with 65 mg/kg streptozotocin. Thirty days later, diabetic nephropathy (DN) was confirmed, and the DN rats received intra-arterial 2 Â 10 6 MSC (n ¼ 14) or an equal volume of control medium (n ¼ 10). On day 90 post-DN induction (60 days after MSC injection), the left and right kidneys of MSC-treated rats and medium-treated rats were harvested, weighed, and processed for histological and correlative protein evaluation. 127  128  129  130  131  132  133  134  135  136  137  138  139  140  141  142  143  144  145  146  147  148  149  150  151  152  153  154  155  156  157  158  159  160  161  162  163  164  165  166  167  168  169  170  171  172  173  174  175  176  177  178  179  180  181  182  183  184  185  186  187  188  189  190  191   192  193  194  195  196  197  198  199  200  201  202  203  204  205  206  207  208  209  210  211  212  213  214  215  216  217  218  219  220  221  222  223  224  225  226  227  228  229  230  231  232  233  234  235  236  237  238  239  240  241  242  243  244  245  246  247  248  249  250  251  252  253  254  255 by semiquantitative analysis software (Media Cybernetics) and normalized to b-actin.
ELISA Measurement of Cytokines
For the analysis of the growth factor production in MSC cultures, the supernatant was collected upon confluence in the third passage. The amounts of VEGF and BMP-7 in cell culture supernatants were quantified by ELISA (R&D Systems, Minneapolis, MN). The renal cortical homogenate VEGF and BMP-7 protein levels were also determined using ELISA. All experiments were performed in triplicate.
Statistical Analysis
All values are presented as the means AE SD. Statistical significance was evaluated using one-way ANOVA with modified t test performed with the Bonferroni correction. The paired t test was used to compare directly the left and right kidneys of an animal. A P value <.05 was considered statistically significant.
RESULTS
Characterization of Rat MSC
Bone marrow-derived MSC from SD rats exhibited typical fibroblast-like morphology. MSC identity was proved by differentiation into osteogenic and adipogenic cells (Figure 2A ). Flow cytometric analysis showed that the MSC were positive for CD29 (99.97%) and CD44 (99.97%) and negative for CD34 (1.53%) and CD45 (.43%).
MSC Localization
Transduction EGFP into MSC by lentiviral vector resulted in a high-transduction efficiency, confirmed by nearly 90% of MSC exhibiting green fluorescence 3 days after transduction (Figure 2A) . At 24 hours after MSC injection, EGFP-positive 257  258  259  260  261  262  263  264  265  266  267  268  269  270  271  272  273  274  275  276  277  278  279  280  281  282  283  284  285  286  287  288  289  290  291  292  293  294  295  296  297  298  299  300  301  302  303  304  305  306  307  308  309  310  311  312  313  314  315  316  317  318  319  320  321   322  323  324  325  326  327  328  329  330  331  332  333  334  335  336  337  338  339  340  341  342  343  344  345  346  347  348  349  350  351  352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373  374  375  376  377  378  379  380  381  382  383  384  385  386 cells were only observed in the left kidney receiving EGFPlabeled MSC but not in the contralateral right kidneys (data not shown). EGFP-positive cells were observed in glomeruli but not in tubulointerstitial areas (data not shown). About 20% and 3% glomeruli showed positive fluorescence at 24 hours and 60 days after MSC infusion, respectively ( Figure 2B ).
Effect of MSC on Physical and Biochemical Parameters
The blood glucose, body weight, kidney weight, kidney to body weight index, and creatinine clearance rate levels of the experimental animals are shown in Table 1 . Compared with medium-treated DN rats, the MSC treatment suppressed the increase in kidney weight, kidney to body weight index, and creatinine clearance rate levels but had no effect on blood glucose and body weight levels on day 60 after MSC infusion.
As shown in Figure 3 , the ratio of urinary albumin to creatinine 30 and 60 days after MSC injection was significantly lower in MSC-treated DN rats than in medium-treated rats, suggesting that MSC have an antiproteinuric effect in DN rats.
Renal Histopathological and Ultrastructural Changes
Light microscopy studies (PAS-staining) were performed to determine the extent of the glomerular damage ( Figure 4A ). As shown in Figure 4A , 90 days after STZ injection, the left and right kidneys of medium-treated rats and the right kidneys of MSC-treated rats exhibited profound extracellular matrix deposition and frequent fibrin cap formation inside the glomeruli. In contrast, 60 days after MSC injection, there was a significant decrease in mesangial matrix deposition ( Figure 4B ) and in the glomerulosclerotic index ( Figure 4C ) of the left kidneys of MSC-treated rats, compared to the left and right kidneys of medium-treated rats and the right kidneys of MSC-treated rats.
Electron microscopy studies were performed to determine the early structural changes in podocyte morphology ( Figure 5A ). Sixty days after MSC injection, compared with the left and right kidneys of medium-treated rats and the right kidneys of MSC-treated rats, the MSC-injected kidneys exhibited a significant improvement in ultrastructural abnormalities, such as loss of podocytes ( Figure 5B ), GBM thickening ( Figure 5C ), and podocyte foot process effacement ( Figure 5D ).
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Oil Red O staining was performed to determine the renal accumulation of neutral lipids. As shown in Figure 2C , 60 days after MSC injection, approximately 10% of the MSCtreated glomeruli contained fat cells (Figure 2Ca ). There was a focal accumulation of oil red O staining in the glomeruli of MSC-treated rats (Figure 2Cb ) and almost no staining in the glomeruli of medium-treated rats or in the right glomeruli of MSC-treated rats (data not shown). Electron microscopy showed the individual large vacuoles as well as several small droplets within the glomerular podocyte cells (Figure 2Cc ).
Effect of MSC on the Renal Expression of Nephrin and Podocin
To further reveal the mechanism responsible for the prevention of albuminuria in MSC-treated diabetic rats, we studied the expression of nephrin and podocin proteins, which are the 2 major proteins involved in the formation of a slit diaphragm. Comparing the left kidneys of mediumtreated rats with the right kidneys of MSC-treated rats, MSC treatment led to a significant improvement in the loss of glomerular nephrin and podocin staining ( Figure 6A ).
In line with the results from immunofluorescence staining, western blotting analysis showed that MSC injection significantly attenuated the diabetic-induced decrease of glomerular nephrin and podocin expression, compared with the left kidneys of medium-treated rats and the right kidneys of MSC-treated rats ( Figure 6B ).
MSC Express High Levels of VEGF and BMP-7
Next, we aimed to evaluate whether MSC could exert their protective effects against podocyte damage in part by increasing VEGF and BMP-7 secretion, which have been shown to be podocyte survival factors to rescue podocytes from injury [17, 18] . Both factors could be secreted by MSC, as previously reported [19] . After 24 hours of incubation, MSC released higher amounts of VEGF (1231 AE 123 pg/mL versus 10 AE 2 pg/mL) and BMP-7 (1868 AE 67 pg/mL versus 49 AE 12 pg/mL) in vitro in cell culture supernatants than in fresh medium ( Figure 7A ).
As shown in Figure 7B , the renal cortical VEGF levels in the left kidneys from MSC-treated rats (1928 AE 63 pg/mg protein) did not significantly increase on day 60 post-MSC injection compared with the left kidneys of mediumtreated rats (1804 AE 97 pg/mg protein) and the right kidneys of MSC-treated rats (1838 AE 87 pg/mg protein). In contrast, the BMP-7 levels were higher in the left kidneys of MSC-treated rats (1431 AE 39 pg/mg protein) than those in the left kidneys of medium-treated rats (837 AE 61 pg/mg protein) and the right kidneys of MSC-treated rats (889 AE 100 pg/mg protein), suggesting that the protective effects of MSC on podocyte injury in DN may be mediated in part by an increased BMP-7 secretion.
DISCUSSION
MSC are multipotent cells present in bone marrow and in mesenchymal tissues that can differentiate in vitro into adipocytic, chondrocytic, and osteocytic lineages. These cells do not exhibit hemopoietic markers but rather express CD29, CD44, CD105, and alpha smooth muscle actin [10] . In vitro, MSC may give rise to insulin-producing cells [20, 21] . In vivo, MSC may differentiate into renal cells [22, 23] and reconstitute necrotic segments of damaged kidneys. Thus, bone marrow-derived MSC have been used successfully in cell therapy to treat animal models with acute and chronic renal failure, such as ischemia-reperfusion injury, 5/6 nephrectomy, and unilateral ureteral obstruction, as well as in kidney transplantation models [24] . The present study provides clear evidence that although there was no improvement in blood sugar levels, the injected MSC did prevent the development of albuminuria and the loss of podocytes.
The primary advantage of MSC for utilization in cell therapy is the ease with which they can be harvested from the bone marrow, isolated by plastic adherence, and expanded in culture [25] . However, in vitro manipulations may also alter or influence their natural phenotypes, leading to different, as-yet-undefined activities and responses. In this study, we established that adherent, bone marrow-derived, spindle-shaped cells expressed mesenchymal cell phenotypes (CD29, CD44 þ ) rather than CD34 (hematopoietic cell marker) and CD45 (leukocyte marker). In addition, the MSC possessed osteogenic and adipogenic potential; we confirmed with this approach that the subsequently administered cells retained the characteristics of MSC.
We found that adequate homing of MSC to the injured tissue is important for effective therapy. In most studies, MSC is administered through a standard intravenous route. A disadvantage of the systemic intravenous delivery of MSC can be low uptake at the site of injury. Indeed, significant engraftment of injured tissue was observed in some studies [26] [27] [28] , but not all [29, 30] . Schrepfer et al [31] demonstrated that the systemic intravenous route of administration was not appropriate for MSC to reach their site of activation. Zonta [32] showed that the intra-arterial administration of MSC were the most effective route to achieve immunomodulating effects in experimental kidney transplantation, which primarily occurs because large MSC (15 mm to 19 mm) remain trapped in the capillaries of the small lung filter, which in turn causes the inadequate homing of MSC to the web 4C=FPO 517  518  519  520  521  522  523  524  525  526  527  528  529  530  531  532  533  534  535  536  537  538  539  540  541  542  543  544  545  546  547  548  549  550  551  552  553  554  555  556  557  558  559  560  561  562  563  564  565  566  567  568  569  570  571  572  573  574  575  576  577  578  579  580  581   582  583  584  585  586  587  588  589  590  591  592  593  594 injured tissue. However, using the renal artery as the injection route to administer MSC to treat DN may be associated with the following 2 major complications: (1) renal infarcts and loss of function, and (2) ectopic differentiation into adipocytes within glomeruli [33] . Recently, Ho et al [34] demonstrated that multiple intravenous transplantations of MSC effectively restored the long-term blood glucose homeostasis during 15 weeks in STZ-induced diabetic mice; thus, multiple intravenous transplantations of MSC may serve as a new therapeutic strategy for DM patients. The following 2 factors may contribute to MSC for the treatment of DN: (1) blood sugar reduction and (2) renal protective actions of the MSC themselves within the glomeruli. To examine the second factor, we could only choose the renal artery as the injection route instead of systemic administration. In our study, intra-arterial injection led to 20% of glomeruli containing EGFP cells at 24 hours, as observed in the targeted kidney but not in the lung, liver, or spleen (data not shown). However, 60 days after MSC injection, only 3% of glomeruli containing EGFP þ cells were found in MSC-treated kidneys. This low level of engraftment suggests a paracrine, rather than a cell differentiation, contribution to the beneficial effects of the MSC. However, the positive status of the 3% of the glomeruli in the kidney on 60 days after injection is still higher than the 0% in the lung, liver, and spleen and suggests that there was some targeting of the cell therapy to the kidney, likely due to the renal artery injection. In addition, on day 60 after the injection into a renal artery, approximately 10% of the MSC-treated glomeruli contained cells that exhibited features typical of adipocytes. Electron microscopy showed that large or multiple small fatty vacuoles were found within the glomerular podocyte cells. This phenomenon had been previously reported by Kunter and Rong et al [33] . Although it seems highly likely that these cells originated from the transplanted MSC, the exact mechanisms of MSC transformation are not completely understood. There is evidence that BMP-7 promotes the differentiation of MSC into adipocyte cells [35] . In our study, we found that the expression of BMP-7 was significantly increased in MSC-treated kidneys compared to mediumtreated kidneys, which might help explain these results. These phenomena seems to suggest that the long-term effects of intrarenal, syngeneic MSC transplantation may result in the maldifferentiation of glomerular MSC into adipocytes, thus calling into question the potential benefit of MSC treatment for DN. Taken together, our observation is consistent with the homing capacity of MSC to injured areas via intra-arterial injection in several animal models [11, 36] . Type 1 Diabetes (T1DM), a multifactorial autoimmune disease involving genetic and environmental factors, is hallmarked by the T cell-and macrophages-mediated destruction of pancreatic b-cells, resulting in an irreversible insulin deficiency. STZ or other diabetogenic agents (eg, alloxan) with b-cell-toxic abilities have also been used for producing chemically induced T1DM models through their administration in a large dose or repeated low doses for several days. However, although the STZ model results in hyperglycemia and insulinopenia, it does not bear strong autoimmune features [37] [38] [39] , suggesting that the STZinduced diabetic model is not the equivalent of T1DM.
Although an ideal experimental model of T1DM does not exist, we believe that the use of this STZ model may allow us to obtain valuable information about understanding the molecular bases that contribute to the induction of T1DM in humans.
Recent studies have shown that the systemic administration of MSC into STZ-induced type 1 diabetic C57BL/6 mice [7] and type 2 diabetic NOD/scid mice [8] reduced web 4C=FPO x P < .05 versus fresh medium. (B) Sixty days after MSC injection, there were no significant differences in the renal cortical VEGF levels between the 2 groups. In contrast, BMP-7 levels were significantly higher in the MSC-treated kidneys than in the left kidneys of medium-treated rats or the right kidneys of the MSC-treated rats. The results were presented as the means AE SD. microalbuminuria and preserved normal renal histology. In contrast, untreated diabetic mice presented glomerular hyalinosis and mesangial expansion. The observed renoprotection was associated with a decrease in glycemic levels that could be explained by beta-pancreatic islet regeneration resulting from MSC administration. However, in these studies, neither group demonstrated a significant histologic amelioration of podocyte damage in response to MSC injection; furthermore, their data could not completely distinguish these beneficial effects from a reduction in the serum glucose levels or direct protection of the podocytes. In this study, we successfully established an experimental DN, similar to human type 1 DN and characterized by hyperglycemia and albuminuria, that was also associated with the loss of podocytes, effacement of foot process, widening of foot process, and thickening of the GBM [1, [40] [41] [42] . These changes contribute to progressive glomerulosclerosis, which is a feature of experimental DN. More importantly, our results revealed that MSC effectively ameliorated the phenotypic changes of podocytes in this animal model. Another interesting finding of the present study was that the renoprotective effect of MSC in podocyte injury was only found in the left kidneys, not in the right kidneys, of MSCtreated DN rats. In addition, the renoprotection of MSC were not attributable to glycemic control because MSC via intra-arterial injection had no impact on the elevated serum glucose levels in the diabetic rats. As shown in Table 1 , MSC administration by intra-arterial injection reversed neither hyperglycemia nor body weight loss, the latter of which was associated with poor blood glucose control. Thus, our study clearly suggested that MSC themselves may have had a direct beneficial effect on the ultrastructural alterations in podocytes.
Podocytes play a major role in maintaining the integrity and permeability of the glomerular filtration barrier [43, 44] . In DN, the effacement of podocyte foot processes and the loss of slit diaphragm proteins result in a leakage of albumin and proteinuria [45, 46] . The results of the present study showed that the levels of urinary protein were significantly increased in diabetic rats and could be significantly lowered by MSC. To identify the molecular basis of the observed phenomena, we performed immunostaining for nephrin and podocin, which are constituents of the slit diaphragm and act as a barrier for glomerular capillary walls [47] . Our study revealed that MSC administration could restore the expression of nephrin and podocin in diabetic rats. Hence, our data suggested that the antiproteinuric effects of MSC in diabetes-induced proteinuria may be associated with the restoration of the expressional patterns of podocyte-associated proteins and the maintenance of podocyte foot process in the glomerular filtration barrier.
What are the mechanisms underlying the benefit of MSC in our model? Several recent studies suggest that MSC may mediate their beneficial effects, in part, through paracrine and/or endocrine activity, not through a differentiation mechanism as had been described in some acute renal damage models [48] . To elucidate the potential mechanism of MSC, we focused on evaluating the expression of VEGF and BMP-7 in vitro and in vivo, which are podocyte survival factors secreted by MSC. In this respect, it was noteworthy that our MSC released high amounts of VEGF and BMP-7 in vitro. Our findings were in line with the data of others showing that MSC release VEGF and BMP-7, exerting beneficial effects in chronic kidney disease and acute kidney injury models [19, 49, 40] . We found that the expression of BMP-7 was significantly increased in MSC-treated kidneys compared to medium-treated kidneys. There were small increases in VEGF in MSC-treated kidneys. However, these did not reach statistical significance. These data suggested that MSC exert their protective effects against podocyte damage possibly by increasing BMP-7 secretion. Both in vitro and in vivo studies have indicated that BMP-7 is important for the maintenance of podocyte viability and differentiation [18, 51, 52] . In adult rodent glomeruli in vivo, BMP-7 and its receptors are expressed in podocytes [18] . In cultured mouse podocytes, high glucose decreases BMP-7 expression, and the treatment of podocytes with rhBMP-7 restores podocin and synaptopodin expression [51] . In STZ-induced diabetic mice, the maintenance of renal and glomerular podocyte BMP-7 levels by means of a transgene reduces the onset and progression of nephropathy, especially podocyte dropout [52] . Moreover, the ability of MSC to contribute to podocyte regeneration has been recently shown in a mouse model of Alport syndrome [53] . In addition to BMP-7 and VEGF, MSC can secrete a number of factors, such as HGF, bFGF, and IGF-I, all known to improve renal function in acute kidney injury, mediated by their antiapoptotic, mitogenic, and other cytokine actions [49, 50] . Based on these observations, we deduce that the mechanisms that mediate the protective effects of MSC may be primarily paracrine actions.
In summary, our current study provided further evidence that MSC could not only exert antialbuminuric effects but also, more importantly, prevent early phenotypic changes in podocytes and, subsequently, glomerulosclerosis. We believe that the successful treatment of DN with MSC demonstrated herein holds substantial promise for the development of novel, MSC-based interventions that can prevent the development of DN. However, because our study is an animal study, these findings must be confirmed after further study, such as clinical trial, on human subjects.
ACKNOWLEDGMENTS
We thank the laboratory animal center of Xinqiao hospital for the excellent rat care. We also thank Dr. Xiaohua Guo (University of Utah) for his invaluable advice.
Financial disclosure: This study was supported by the National Natural Science Foundation of China (No. 30570871) and the Natural Science Foundation of Chongqing (No. 2007BB1017).
Conflict of Interest Statement: There are no conflicts of interest to report.
